Effects of subchronic paroxetine administration on night-time endocrinological profiles in healthy male volunteers

Psychoneuroendocrinology

Volumn 25, Issue 4, 2000, Pages 377-388

  Schlosser R ^a   Wetzel, H ^a   Dorr H ^a   Rossbach, W ^a   Hiemke, Ch ^a   Benkert, O ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Antidepressants; Neuroendocrinology; Selective serotonin reuptake inhibitor; Sleep

Indexed keywords

CORTICOTROPIN; HYDROCORTISONE; LUTEINIZING HORMONE; MELATONIN; PAROXETINE; PLACEBO; PROLACTIN; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TESTOSTERONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HORMONE BLOOD LEVEL; HORMONE RELEASE; HUMAN; HUMAN EXPERIMENT; MALE; NIGHT; NORMAL HUMAN; PRIORITY JOURNAL; SLEEP; VOLUNTEER;

ADRENOCORTICOTROPIC HORMONE; ADULT; CIRCADIAN RHYTHM; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ELECTROENCEPHALOGRAPHY; HORMONES; HUMAN GROWTH HORMONE; HUMANS; HYDROCORTISONE; LUTEINIZING HORMONE; MALE; MELATONIN; PAROXETINE; PLACEBOS; PROLACTIN; SEROTONIN UPTAKE INHIBITORS;

EID: 0342905023     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4530(99)00065-7     Document Type: Article

References (25)

1. Arnold M.A., Fernstrom J.D. Administration of anti-somatostatin serum to rats reverses the inhibition of pulsatile growth hormone secretion produced by injection of metergoline but not yohimbine. Neuroendocrinology. 31:1980;194-199.
2. Borup C., Meidahl B., Petersen I.M., Vangtorp A., le-Fevre-Honore P. An early clinical phase II evaluation of paroxetine, a new potent and selective 5HT-uptake inhibitor in patients with depressive illness. Pharmacopsychiatria. 15:1982;183-186.
3. Brown R. Neuroendocrinology. 1994;Cambridge University Press, Cambridge.
4. Calogero A.E., Bagdy G., Szemeredi K., Tartaglia M.E., Gold P.W., Chrousos G.P. Mechanisms of serotonin receptor agonist-induced activation of the hypothalamic-pituitary-adrenal axis in the rat. Endocrinology. 126:1990;1888-1894.
5. Calogero A.E., Bernardini R., Margioris A.N., Bagdy G., Gallucci W.T., Munson P.J., Tamarkin L., Tomai T.P., Brady L., Gold P.W. et al. Effects of serotonergic agonists and antagonists on corticotropin-releasing hormone secretion by explanted rat hypothalami. Peptides. 10:1989;189-200.
6. Chaput Y., de-Montigny C., Blier P. Presynaptic and postsynaptic modifications of the serotonin system by long-term administration of antidepressant treatments. An in vivo electrophysiologic study in the rat. Neuropsychopharmacology. 5:1991;219-229.
7. de-Montigny C., Chaput Y., Blier P. Modification of serotonergic neuron properties by long-term treatment with serotonin reuptake blockers. Journal of Clinical Psychiatry. 51(Suppl B):1990;4-8.
8. Holsboer F., Muller O.A., Winter K., Doerr H.G., Sippell W.G. Effect of serotonin uptake inhibition by zimelidine on hypothalamic-pituitary-adrenal activity. Psychopharmacology (Berlin). 80:1983;85-87.
9. Jakovljevic, M., Plavsic, V., Trbovic, M., Korsic, M., Mewett, S., 1990. Acute neuroendocrine effects of paroxetine. CINP Kyoto CM/4/200/5/90.
10. Kaye C.M., Haddock R.E., Langley P.F., Mellows G., Tasker T.C., Zussman B.D., Greb W.H. A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatrica Scandinavica Supplement. 350:1989;60-75.
11. Laursen A.L., Mikkelsen P.L., Rasmussen S., le-Fevre-Honore P. Paroxetine in the treatment of depression - a randomized comparison with amitriptyline. Acta Psychiatrica Scandinavica. 71:1985;249-255.
12. Levy A.D., Van-de-Kar L.D. Endocrine and receptor pharmacology of serotonergic anxiolytics, antipsychotics and antidepressants. Life Sciences. 51:1992;83-94.
13. Murakami Y., Kato Y., Kabayama Y., Tojo K., Inoue T., Imura H. Involvement of growth hormone (GH)-releasing factor in GH secretion induced by serotoninergic mechanisms in conscious rats. Endocrinology. 119:1986;1089-1092.
14. Nemeroff C.B. The corticotropin releasing factor (CRF) hypothesis in depression: new findings and new directions. Molecular Psychiatry. 1:1996;336-342.
15. Nestler E.J Antidepressant treatments in the 21st century. Biological Psychiatry. 44:1998;526-533.
16. O'Keane V., McLoughlin D., Dinan T.G. D-fenfluramine-induced prolactin and cortisol release in major depression: response to treatment. Journal of Affective Disorders. 26:1992;143-150.
17. Reist C., Helmeste D., Albers L., Chhay H., Tang S.W. Serotonin indices and impulsivity in normal volunteers. Psychiatry Research. 60:1996;177-184.
18. Reul J.M., Stec I., Soder M., Holsboer F. Chronic treatment of rats with the antidepressant amitriptyline attenuates the activity of the hypothalamic-pituitary-adrenocortical system. Endocrinology. 133:1993;312-320.
19. Röschke J., Kögel P., Schlösser R., Wagner P., Mann K., Rossbach W., Benkert O. Analysis of sleep EEG microstructure in subchronic paroxetine treatment of healthy subjects. Psychopharmacology. 132:1997;44-49.
20. Sargent P.A., Williamson D.J., Cowen P.J. Brain 5-HT neurotransmission during paroxetine treatment. British Journal of Psychiatry. 172:1998;49-52.
21. Schlösser R., Röschke J., Rossbach W., Benkert O. Conventional and spectral power analysis of all-night sleep EEG after subchronic treatment with paroxetine in healthy male volunteers. European Neuropsychopharmacology. 8:1998;273-278.
22. Thomas D.R., Nelson D.R., Johnson A.M. Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology (Berlin). 93:1987;193-200.
23. Timotijevic, I., Milovanovic, V., 1990. The dexamethasone suppression test-a possible indicator of clinical and biological stabilization during depressive illness. CINP Kyoto, CM/4/199/5/90.
24. Tuomisto J., Mannisto P. Neurotransmitter regulation of anterior pituitary hormones. Pharmacological Reviews. 37:1985;249-332.
25. Van-de-Kar L.D. Neuroendocrine pharmacology of serotonergic (5-HT) neurons. Annual Reviews of Pharmacology and Toxicology. 31:1991;289-320.